Hong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B

Stock News09:12

According to the latest disclosure from the Hong Kong Stock Exchange, a notable change in share custody was recorded on September 3rd for GENFLEET-B (02595). The total market value of the shares held in custody reached HK$1.955 billion, representing 19.65% of the company's issued shares.

A shareholder of the company has deposited 43.7309 million shares into Standard Chartered Bank (Hong Kong), resulting in an increase of 12.44% in the shareholder's disclosed holding percentage. This custody movement typically indicates a transfer of physical share certificates into electronic form, often preceding trading or other corporate actions.

In a separate development, GENFLEET-B recently announced that its drug candidate, GFH375, has advanced into a Phase II clinical study for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation. The study will evaluate the drug in three different treatment regimens: as a monotherapy, in combination with an EGFR monoclonal antibody (cetuximab), and in combination with chemotherapy (pemetrexed).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117075643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-04 09:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117075643","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B","media":"Stock News","content":"<p>According to the latest disclosure from the Hong Kong Stock Exchange, a notable change in share custody was recorded on September 3rd for <b>GENFLEET-B</b> (02595). The total market value of the shares held in custody reached HK$1.955 billion, representing 19.65% of the company's issued shares.<br><br>A shareholder of the company has deposited 43.7309 million shares into <b>Standard Chartered Bank (Hong Kong)</b>, resulting in an increase of 12.44% in the shareholder's disclosed holding percentage. This custody movement typically indicates a transfer of physical share certificates into electronic form, often preceding trading or other corporate actions.<br><br>In a separate development, <b>GENFLEET-B</b> recently announced that its drug candidate, GFH375, has advanced into a Phase II clinical study for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation. The study will evaluate the drug in three different treatment regimens: as a monotherapy, in combination with an EGFR monoclonal antibody (cetuximab), and in combination with chemotherapy (pemetrexed).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Exchange Data Reveals Significant Custody Transfer for GENFLEET-B\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-04 09:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest disclosure from the Hong Kong Stock Exchange, a notable change in share custody was recorded on September 3rd for <b>GENFLEET-B</b> (02595). The total market value of the shares held in custody reached HK$1.955 billion, representing 19.65% of the company's issued shares.<br><br>A shareholder of the company has deposited 43.7309 million shares into <b>Standard Chartered Bank (Hong Kong)</b>, resulting in an increase of 12.44% in the shareholder's disclosed holding percentage. This custody movement typically indicates a transfer of physical share certificates into electronic form, often preceding trading or other corporate actions.<br><br>In a separate development, <b>GENFLEET-B</b> recently announced that its drug candidate, GFH375, has advanced into a Phase II clinical study for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation. The study will evaluate the drug in three different treatment regimens: as a monotherapy, in combination with an EGFR monoclonal antibody (cetuximab), and in combination with chemotherapy (pemetrexed).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1117075643","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117075643","pubTimestamp":1788484341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest disclosure from the Hong Kong Stock Exchange, a notable change in share custody was recorded on September 3rd for GENFLEET-B (02595). The total market value of the shares held...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","02595":"劲方医药-B","BK1161":"生物科技","BK1574":"生物医药B类股","BK1515":"抗疫概念"},"translate_title":"香港联交所数据显示 GENFLEET-B 的重大托管转移","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02595":1},"content_text":"According to the latest disclosure from the Hong Kong Stock Exchange, a notable change in share custody was recorded on September 3rd for GENFLEET-B (02595). The total market value of the shares held in custody reached HK$1.955 billion, representing 19.65% of the company's issued shares.A shareholder of the company has deposited 43.7309 million shares into Standard Chartered Bank (Hong Kong), resulting in an increase of 12.44% in the shareholder's disclosed holding percentage. This custody movement typically indicates a transfer of physical share certificates into electronic form, often preceding trading or other corporate actions.In a separate development, GENFLEET-B recently announced that its drug candidate, GFH375, has advanced into a Phase II clinical study for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12D mutation. The study will evaluate the drug in three different treatment regimens: as a monotherapy, in combination with an EGFR monoclonal antibody (cetuximab), and in combination with chemotherapy (pemetrexed).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117075643","isCrawlerRequest":true}